Chinese vape manufacturers are increasingly incorporating nicotine analogs, particularly 6-methyl-nicotine, into their products to circumvent strict US regulatory frameworks. These synthetic compounds, which underwent extensive research by major tobacco corporations decades ago but were deemed too risky for commercial distribution, present potentially stronger addictive properties than traditional nicotine. This regulatory arbitrage strategy exploits loopholes in international trade laws, raising significant public health concerns about consumer safety and long-term health implications of unregulated vaping substances.

Summary auto-generated by AI from the original publisher's content. Editorial standards.